AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 251 min read$COR

Campbell Elizabeth S sold $3.7M of COR

Campbell Elizabeth S (Executive Vice President) sold 11,300 shares of Cencora, Inc. (COR) at $324.12 ($3.66M total) on 2026-08-24.

Original reporting
SEC EDGAR · Campbell Elizabeth S
Published Aug 25, 2026, 8:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$COR
Bearish
medium confidence
Mentioned
$COR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORBearishLow
01

Why it matters

The insider sell is material for short‑term traders monitoring insider activity.

02

Market read

Provides fresh insider‑sell data for COR, useful for short‑term positioning.

03

What to watch

No pre‑arranged 10b5‑1 plan; the sale may be driven by personal liquidity needs.

Relevance 6/10Novelty 7/10Timing: post‑market 2026‑08‑24

Background

Form 4 filings disclose insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$CORBearishMedium confidence
Context

Executive Vice President sold 11,300 shares for $3.66M, reducing her stake to 19,455 shares.

Expected impact

Potential short-term downward pressure on COR stock.

Evidence & confidence

A $3.6M sale by an EVP is material for a mid‑cap stock and is the first public disclosure of the transaction.

Market effects

Sector

Minimal impact on the pharmaceutical distribution sector beyond the specific insider activity.

Regional

Limited to U.S. markets where COR trades.

Global

Low global relevance; primarily of interest to investors in COR.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Executive
    Campbell Elizabeth S

    Executive Vice President of Cencora, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

COR insider trading history →

Related articles

AUG 23
$MCKMedAI 8/10

and Getting Worse. Here Are 2 Stocks That Turn Rising Prices Into Rising Profits.

McKesson (MCK) and Cencora (COR) are positioned to benefit from certain drug price inflation due to contractual provisions. McKesson reported $403.4B revenue and $39.11 EPS for fiscal 2026, with Q1 2027 revenue at $105.4B and EPS at $9.93. Cencora generated $321.3B revenue in fiscal 2025, with Q2 revenue at $78.4B and EPS at $4.75. Both companies have raised EPS forecasts.

aol.com3 min
AUG 21
$MCKHighAI 9/10

With Price-Increase Clauses, These Two Drug Distributors Can Withstand ‘Trumpflation’

McKesson (MCK) and Cencora (COR) benefit from drug price increases due to inflation-based compensation clauses. McKesson reported $403.4B revenue in 2026, up 12%, and raised EPS guidance. Cencora posted $321.3B revenue in 2025, up 3.8%, and increased EPS guidance. Both companies' contracts allow gains from manufacturer price hikes, but risks include regulation and cost pressures.

nai500.com3 min
AUG 20
$CVSMedAI 8/10

Health Insurance Providers Stocks Q2 Teardown: Clover Health (NASDAQ:CLOV) Vs The Rest

CVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. Despite strong earnings, its stock fell 10.2% to $93.76. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, causing a 15.3% stock drop to $25.58. Cencora (COR) reported $84.75B revenue, up 5.1% YoY, in line with expectations, with a 3.2% stock increase to $316.20. UnitedHealth (UNH) reported $112B revenue, flat YoY, beating estimates, but its stock fell 7.1% to $388.62.

finance.yahoo.com3 min
AUG 13
$CORMed

Is Wall Street Bullish or Bearish on Cencora Stock?

Cencora (COR) is a pharma distributor with a $65B market cap. The stock lagged the S&P 500 over 1 year and fell in 2026. After Q3 2026 results on Aug. 5, revenue was $84.8B (below estimates) but adjusted EPS was $4.48 (above). Full-year EPS guidance is $17.75-$17.95. Morgan Stanley raised its COR target to $346.

yahoo.com4 min
AUG 12
$CORMed

Why is Cencora stock sliding today?

Cencora (COR) shares fell 4.2% after the company said some Walgreens volume handled outside its prime vendor agreement began shifting to rival distributors as of July 1, 2026. Cencora said its core prime agreement remains intact and reaffirmed FY2026 adjusted diluted EPS guidance of $17.75 to $17.95. Wells Fargo raised its COR price target to $395. CFO James Cleary plans to sell about 20,000 shares.

investing.com4 min